Fig. 4

EMID2 overexpression inhibits the growth and dissemination of murine and human cancers. A Representative hematoxylin/eosin staining of total lung and zoomed fields of LG tumor mass. B Number of LG tumor foci. C Area covered by LG cells. D Representative images of total pancreas and zoomed fields injected with KPC cells. KPC cells are stained for Ki67. Nuclei are counterstained with hematoxylin. E Number of KPC tumor foci per pancreas. F Area covered by Ki67⁺ KPC cells. G Representative images of total pancreas and zoomed fields of KC mice. Cancer cells are stained for Ki67. Nuclei are counterstained with hematoxylin. H Pancreas/body weight for each mouse. I Number of tumor foci per pancreas. J Area covered by Ki67⁺ cancer cells. K. Area covered by YAP⁺ cancer cells on tumor area. L. Representative images of the pancreas of KC mice stained for YAP. M. Representative images of wound healing assay with EGFP⁺ Panc1 cells co-cultured human fibroblasts overexpressing EMID2 or control fibroblasts, at the indicated time points. N. Wound closure at T20 relative to T0. O, P. Kaplan-Meier curves of patients affected by pancreatic adenocarcinoma (PAAD) and lung adenocarcinoma (LUAD), according to the expression levels of EMID2, at the indicated time points from diagnosis. Q. Forest plot indicating the Hazard Ratio (HR) for the most aggressive human solid cancers. GBMLGG: glioblastoma multiforme and low-grade glioma, LGG: low grade glioma, PAAD: pancreatic adenocarcinoma, LIHC: liver hepatocellular carcinoma, BLCA: bladder urothelial carcinoma, LUAD: lung adenocarcinoma, LUSC: lung squamous cell carcinoma, CHOL: cholangiocarcinoma, ESCA: esophageal carcinoma, MESO: mesothelioma. Square size reflects the weight of the significance. Source: TCGA database. Scale bar in A (whole lung), D, G (whole pancreas) 1 mm, in A, D, G (magnification) 200 μm, in L, M 50 μm. In B, C, E, F, H, I, J, K, N data are shown as mean ± SEM and were analyzed by one-way ANOVA with Student-Newman-Keuls correction. *p < 0.05, ***p < 0.001